The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., & Parks, W. P. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1417 · Cited by 2,289
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,603
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
Making antibody fragments using phage display libraries
Clackson, T., Hoogenboom, H. R., Griffiths, A. D., & Winter, G. (1991) · Nature · doi:10.1038/352624a0 · Cited by 1,203
Buday, L., & Downward, J. (1993) · Cell · doi:10.1016/0092-8674(93)90146-h · Cited by 1,079
Selecting and screening recombinant antibody libraries
Hoogenboom, H. R. (2005) · Nature Biotechnology · doi:10.1038/nbt1126 · Cited by 973
A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles.
Cohen, S., Ushiro, H., Stoscheck, C., & Chinkers, M. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68224-4 · Cited by 776
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., & Muyldermans, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01062-4 · Cited by 768
The ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552
Antibody phage display technology and its applications
Hoogenboom, H. R., de Bruı̈ne, A. P., Hufton, S. E., Hoet, R. M., Arends, J.-W., & Roovers, R. C. (1998) · Immunotechnology · doi:10.1016/s1380-2933(98)00007-4 · Cited by 512
Self-citationPotent enzyme inhibitors derived from dromedary heavy-chain antibodies
Lauwereys, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3512 · Cited by 490
HONEGGER, A. (1987) · Cell · doi:10.1016/0092-8674(87)90147-4 · Cited by 475
Impact of EGFR expression on colorectal cancer patient prognosis and survival
Spano, J.-P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., Attar, A., Benichou, J., Martin, A., Morere, J.-F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi006 · Cited by 462
Herbst, R. S., Arquette, M., Shin, D. M., Dicke, K., Vokes, E. E., Azarnia, N., Hong, W. K., & Kies, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.120 · Cited by 402
Merlino, G. T., Xu, Y.-H., Ishii, S., Clark, A. J. L., Semba, K., Toyoshima, K., Yamamoto, T., & Pastan, I. (1984) · Science · doi:10.1126/science.6200934 · Cited by 401
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Self-citationRowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
Els Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 300
Nguyen, V. K., Hamers, R., Wyns, L., & Muyldermans, S. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.921 · Cited by 299
(2004) · The Women's Oncology Review · doi:10.3109/14733400410001727592 · Cited by 288
Frenken, L. G. J., van der Linden, R. H. J., Hermans, P. W. J. J., Bos, J. W., Ruuls, R. C., de Geus, B., & Verrips, C. T. (2000) · Journal of Biotechnology · doi:10.1016/s0168-1656(99)00228-x · Cited by 286
Design and application of diabodies, triabodies and tetrabodies for cancer targeting
Todorovska, A., Roovers, R. C., Dolezal, O., Kortt, A. A., Hoogenboom, H. R., & Hudson, P. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00342-2 · Cited by 272
Self-citationEfficient tumor targeting by single‐domain antibody fragments of camels
Cortez‐Retamozo, V., Lauwereys, M., Hassanzadeh Gh., G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P., & Revets, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10212 · Cited by 260
Self-citationNanobodies as novel agents for cancer therapy
Revets, H., De Baetselier, P., & Muyldermans, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.111 · Cited by 254
Self-citationThe Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer
Raben, D., Helfrich, B., Chan, D. C., Ciardiello, F., Zhao, L., Franklin, W., Barón, A. E., Zeng, C., Johnson, T. K., & Bunn, P. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.795.11.2 · Cited by 244
Herbst, R. S., & Langer, C. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31525 · Cited by 237
Foon, K. A., Yang, X.-D., Weiner, L. M., Belldegrun, A. S., Figlin, R. A., Crawford, J., Rowinsky, E. K., Dutcher, J. P., Vogelzang, N. J., Gollub, J., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.098 · Cited by 218
Biophysical Properties of Camelid VHH Domains Compared to Those of Human VH3 Domains
Ewert, S., Cambillau, C., Conrath, K., & Plückthun, A. (2002) · Biochemistry · doi:10.1021/bi011239a · Cited by 184
Rowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178
Oncogenic growth factor receptors: implications for signal transduction therapy
Mosesson, Y., & Yarden, Y. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.005 · Cited by 166
Bleeker, W. K., van Bueren, J. J. L., van Ojik, H. H., Gerritsen, A. F., Pluyter, M., Houtkamp, M., Halk, E., Goldstein, J., Schuurman, J., van Dijk, M. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4699 · Cited by 152
Targeting of adenoviral vectors through a bispecific single-chain antibody
Haisma, H. J., Grill, J., Curiel, D. T., Hoogeland, S., van Beusechem, V. W., Pinedo, H. M., & Gerritsen, W. R. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700198 · Cited by 147
Bremer, E., Samplonius, D. F., van Genne, L., Dijkstra, M. H., Kroesen, B. J., de Leij, L. F. M. H., & Helfrich, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413673200 · Cited by 106
Heitner, T., Moor, A. C. E., Garrison, J. L., Marks, C. B., Hasan, T. G., & Marks, J. D. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00340-9 · Cited by 105
Induced refolding of a temperature denatured llama heavy‐chain antibody fragment by its antigen
Dolk, E., van Vliet, C., Pérez, J. M. J., Vriend, G., Darbon, H., Ferrat, G., Cambillau, C., Frenken, L. G. J., & Verrips, T. C. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20378 · Cited by 80
Verheesen, P., ten Haaft, M. R., Lindner, N. M., Verrips, C. T., & de Haard, J. J. W. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2003.09.006 · Cited by 78
de Haard, H., Bezemer, S., Ledeboer, A. M., Müller, W. H., Boender, P. J., Moineau, S., Coppelmans, M.-C., Verkleij, A. J., Frenken, L. G. J., & Verrips, C. T. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.13.4531-4541.2005 · Cited by 77
Self-citationRoovers, R. C., Henderikx, P., Helfrich, W., van der Linden, E. P. M., Reurs, A. W., de Bruı̈ne, A. P., Arends, J. W., de Leij, L., & Hoogenboom, H. R. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.700 · Cited by 57
Self-citationBruell, D., Stöcker, M., Hühn, M., Redding, N., Kupper, M. B., Schumacher, P., Paetz, A., Bruns, C. J., Haisma, H. J., Fischer, R., et al. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.4.1179 · Cited by 53
Hayashi, H., Asano, R., Tsumoto, K., Katayose, Y., Suzuki, M., Unno, M., Kodama, H., Takemura, S.-I., Yoshida, H., Makabe, K., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0465-9 · Cited by 42
Lange, I. G., Daxenberger, A., & MEYER, H. H. D. (2001) · Veterinary Immunology and Immunopathology · doi:10.1016/s0165-2427(01)00376-2 · Cited by 22
Cited by
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
“Therefore, VHHs have been targeted to normally long-lived serum proteins such as albumin (Coppieters et al. 2006; Roovers et al. 2007) or immunoglobulin (Harmsen et al. 2005a) using bispecific VHHs recognizing these serum proteins in addition to the therapeutic target, resulting in half-lives that…”
BackgroundInfluentialA general protocol for the generation of Nanobodies for structural biology
Pardon, E., Laeremans, T., Triest, S., Rasmussen, S. G. F., Wohlkönig, A., Ruf, A., Muyldermans, S., Hol, W. G. J., Kobilka, B. K., & Steyaert, J. (2014) · Nature Protocols · doi:10.1038/nprot.2014.039 · Cited by 790
Self-citationThe therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
Metadata
- Authors
- Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2006-05-30
- Volume
- 56
- Issue
- 3
- Pages
- 303-317
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2030205190
- Cited by
- 346
- References
- 51
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.